Welcome to our dedicated page for Bridgebio Pharma news (Ticker: BBIO), a resource for investors and traders seeking the latest updates and insights on Bridgebio Pharma stock.
BridgeBio Pharma Inc (BBIO) news coverage focuses on clinical trial results, regulatory developments, and pipeline updates for the company's genetic disease and cancer therapies. As a commercial-stage biotechnology company with multiple drug development programs, BridgeBio generates news through data readouts from ongoing clinical trials, FDA interactions, product approvals, and commercial performance metrics for marketed therapies.
Investors following BridgeBio news will find announcements related to Phase 1, Phase 2, and Phase 3 trial enrollments and results, presentations at medical conferences, regulatory submissions and decisions, patent developments, and business development activities. The company also reports quarterly financial results that include research and development expenses, commercial revenue from approved products, cash positions, and updated clinical timelines for pipeline programs.
Key news categories include cardiovascular disease programs, rare genetic disorder therapies, oncology candidates, partnership announcements, manufacturing agreements, and intellectual property milestones. Given the binary nature of biotechnology development, where clinical trial results and regulatory decisions can significantly impact company trajectory, staying informed about BridgeBio's pipeline progress helps investors understand the company's execution against development plans and commercial strategies.
BridgeBio Pharma (BBIO) announced the Japanese approval of Beyonttra™ (acoramidis) for treating ATTR-CM (transthyretin-mediated amyloid cardiomyopathy) in adults. The approval stems from successful Phase 3 trials, including a Japanese study reporting 0% mortality over 30 months and a global ATTRibute-CM trial showing significant benefits.
Key clinical achievements include:
- 42% reduction in composite all-cause mortality and recurrent cardiovascular-related hospitalization events at Month 30
- 50% reduction in cumulative cardiovascular-related hospitalization events at Month 30
- Benefits observed as early as 3 months into treatment
Through its partnership with Alexion, AstraZeneca Rare Disease, BridgeBio will receive a $30 million milestone payment and low double-digit royalties on Japanese sales. Commercial launch is planned for first half 2025.
BridgeBio Pharma (Nasdaq: BBIO) has announced the presentation of cardiovascular outcomes data from their ATTRibute-CM Phase 3 study of acoramidis in ATTR-CM at the upcoming American College of Cardiology (ACC) Annual Scientific Sessions in Chicago, March 29-31, 2025.
The company will present seven studies, including five flatboard poster presentations and two moderated posters, focusing on various aspects of acoramidis treatment in ATTR-CM patients. Key presentations include:
- Acoramidis's impact on serum TTR levels in wild-type and variant ATTR-CM patients
- Improvements in NYHA Class at Month 30 versus placebo
- Effects of combining acoramidis with tafamidis
- Primary endpoint efficacy results and NT-proBNP sensitivity analyses
- Relationship between early serum transthyretin increase and reduced cardiovascular hospitalizations
- Geographic healthcare disparities in ATTR-CM diagnosis
BridgeBio Pharma (Nasdaq: BBIO) has announced new equity grants approved by its compensation committee on March 19, 2025. The grants consist of restricted stock units totaling 30,782 shares, awarded to 10 new employees.
The vesting schedule specifies that one-fourth of each employee's shares will vest on February 16, 2026, followed by quarterly vesting of one-twelfth of the remaining shares, contingent on continued employment. These inducement grants were made under BridgeBio's Amended and Restated 2019 Inducement Equity Plan, in accordance with Nasdaq Listing Rule 5635(c)(4).
BridgeBio Pharma (Nasdaq: BBIO) announced a leadership transition as Thomas Trimarchi, Ph.D. has been appointed as President and Chief Financial Officer (CFO). Dr. Trimarchi, who recently became Principal Financial Officer, will continue leading the company's FP&A and accounting operations.
The current CFO, Brian Stephenson, Ph.D., is departing for personal reasons and will transition to a consulting role. The company confirmed that Dr. Stephenson's departure is not related to any disagreements regarding company operations, policies, or practices.
Deep Track Capital, owning 14.34% of Dynavax Technologies (NASDAQ: DVAX), has sent a letter to the company's Board expressing concerns about capital allocation and governance. The letter highlights strong shareholder support for Deep Track's position and criticizes the Board's recent decision to issue $265 million in convertible notes instead of using available cash.
The investment firm nominated four candidates for the Board election at the 2025 Annual Meeting, seeking to improve corporate strategy and governance. Deep Track emphasizes that DVAX stock has risen 34% since their involvement in October 2024, while the biotech sector indices declined. They dispute the company's claim that they seek board control, noting they aim for four seats on a nine-member board.
The letter criticizes the Board's defensive tactics and highlights widespread shareholder support for having Deep Track representation, focusing on Heplisav's potential, and improving capital allocation strategies.
BridgeBio Oncology Therapeutics (BBOT) and Helix Acquisition Corp. II (HLXB) have announced a business combination agreement to create a publicly listed biotechnology company. The transaction, expected to complete in Q3 2025, will provide total proceeds of $450 million, combining HLXB's trust account funds and a $260 million PIPE financing led by Cormorant Asset Management.
The combined entity will focus on developing therapies for RAS and PI3Kα malignancies through three lead programs:
- BBO-8520: A KRASG12C inhibitor in Phase 1 trials for non-small cell lung cancer
- BBO-10203: An oral small molecule in Phase 1 trials for various cancers
- BBO-11818: A pan-KRAS inhibitor expected to begin patient dosing in H1 2025
The combined company is projected to have an implied pro forma equity value of $949 million at closing, assuming a $10.36 share price and no redemptions. BBOT shareholders will roll 100% of their equity into the combined company.
BridgeBio Pharma (BBIO) has priced a $500 million convertible senior notes offering due 2031, with an additional $75 million option for initial purchasers. The notes, priced at a 1.75% interest rate with a 45% conversion premium, will be convertible into cash, company shares, or a combination thereof.
The company expects net proceeds of approximately $489.5 million (or $563.0 million if the additional option is exercised). These funds will be used to repay outstanding borrowings under its Financing Agreement with Blue Owl , which accounted for $51.5 million in interest payments in 2024. Additionally, $48.3 million will be used to repurchase 1,405,411 shares at $34.35 per share.
The notes will mature on March 1, 2031, with an initial conversion rate of 20.0773 shares per $1,000 principal amount, equivalent to a conversion price of $49.81 per share.
BridgeBio Pharma (BBIO) has announced plans to offer $500 million in convertible senior notes due 2031, with an additional $75 million option for initial purchasers. The company will use the proceeds to repay outstanding borrowings under its Financing Agreement with Blue Owl , which accounted for approximately $51.5 million in interest payments in 2024.
The company plans to use up to $50 million to repurchase shares of its common stock from certain note purchasers in private transactions. The notes will mature on March 1, 2031, bearing semi-annual interest, and will be convertible into cash, shares, or a combination thereof. BridgeBio may redeem the notes after March 6, 2028, if the stock price exceeds 130% of the conversion price for a specified period.
This refinancing strategy aims to strengthen the balance sheet without increasing total liabilities, while lowering interest expenses and extending debt maturity.
BridgeBio Pharma (BBIO) reported its Q4 and full-year 2024 results, highlighting significant progress with Attruby™. Since FDA approval in November 2024, 1,028 unique patient prescriptions have been written by 516 prescribers. The drug was also approved as BEYONTTRA™ in the EU in February 2025, triggering a $75 million milestone payment.
The company ended Q4 2024 with $681.2 million in cash, up from $392.6 million year-over-year. Revenue for 2024 increased to $221.9 million from $9.3 million in 2023, primarily due to licensing agreements and initial Attruby sales. Operating expenses rose to $814.9 million in 2024 from $616.7 million in 2023.
Three global registrational studies are fully enrolled: FORTIFY, CALIBRATE, and PROPEL 3, with results expected before end of 2025. The company expects to receive $105 million in regulatory milestones in H1 2025 from acoramidis approvals in Europe and Japan.
BridgeBio Pharma (BBIO) has announced it will release its Q4 and full-year 2024 financial results on February 20, 2025. The announcement will include updates on Attruby's commercialization progress and the company's late-stage clinical pipeline. Starting with Q1 results, expected in late April or early May, the company will begin hosting earnings calls, as previously outlined in its JPM presentation.
FAQ
What is the current stock price of Bridgebio Pharma (BBIO)?
What is the market cap of Bridgebio Pharma (BBIO)?
